Publikationen in Zusammenarbeit mit Forschern von Baylor College of Medicine (12)

2023

  1. An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps

    Cardiovascular Drugs and Therapy, Vol. 37, Núm. 6, pp. 1205-1223

  2. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370

  3. Role of the Meningeal Lymphatics in Stroke

    Stroke

  4. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 6, pp. 570-582

2008

  1. Aliskiren - The first of a new class of antihypertensive

    Drugs in Context, Vol. 4, Núm. 1, pp. 105-120

  2. Cervarix - Preventing cervical cancer and other diseases related to HPV

    Drugs in Context, Vol. 4, Núm. 1, pp. 59-70

  3. Coversyl Plus - Treating hypertension and improving clinical outcomes in T2D and other high risk groups

    Drugs in Context, Vol. 4, Núm. 1, pp. 71-84

  4. Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia

    Drugs in Context, Vol. 4, Núm. 1, pp. 85-104

  5. Gardasil - Preventing cervical cancer and other diseases related to HPV

    Drugs in Context, Vol. 4, Núm. 1, pp. 29-40

  6. Inegy - Effective combination treatment to target LDL-C levels

    Drugs in Context, Vol. 4, Núm. 1, pp. 41-58

  7. Telmisartan - An effective antihypertensive for 24-hour blood pressure control

    Drugs in Context, Vol. 4, Núm. 1, pp. 1-14

  8. Tiotropium - Advancing the treatment of COPD

    Drugs in Context, Vol. 4, Núm. 1, pp. 15-28